Ovarian Cancer Trial, Recruiting NCT06216496 Sponsor: University Hospital, Grenoble Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06216496
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed (confirmed by tissue testing) with a specific type of advanced ovarian cancer called high-grade serous ovarian cancer that cannot be operated on straight away (stage III or IVa), and you are being treated at Grenoble Alpes University Hospital in France.
  • You are enrolled in the French social security system.
  • You are able to understand and follow the instructions for the trial, and you are willing to sign a written consent form.

Who may not be able to join:

  • You have a serious ongoing health condition that requires long-term medication (such as organ failure or diabetes), or you have a history of certain conditions that affect how your body processes amino acids (building blocks of protein) — for example, certain rare metabolic disorders (confirm with trial site).
  • You follow a vegetarian or vegan diet.
  • The veins in your arm are difficult to access for blood draws or injections.
  • You are pregnant, currently breastfeeding, have recently given birth, are in prison or under a legal protection order (as defined by French law).
  • You have received more than €4,500 in payments for taking part in other medical research studies in the 12 months before this trial.
  • You have significant abnormal blood test results that are not explained by your ovarian cancer diagnosis (confirm with trial site).
  • You have cancer that has spread to your liver (liver metastases).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
11 March 2024
Est. completion
1 April 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

metabolism of each amino acid, in women with non-immediately resectable ovarian cancer (with or without peritoneal metastases) of high-grade serous type.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov